The clinical trial concerns the use of an innovative \"anti-emetic\" drug (that is, anti-vomiting and nausea) in subjects affected by endometrial cancer. It is addressed to patients who have never received chemotherapy before and are about to start a treatment with platinum and taxanes with or without immunotherapy for endometrial cancer.
The primary objective of the study is to learn if the drug is able to avoid the occurrence of vomiting and post- nausea chemotherapy within 120 hours after cycle 1 with carboplatin and paclitaxel with or without immunotherapy.
Partecipants will take the drug before the chemotherapy/immunotherapy (single dose at day one of each cycle of therapy, that is one capsule before treatment). The entire duration of participation in the study may extend to the fourth cycle of chemotherapy/immunotherapy.
Patients will fill in questionnaires and keep a diary of the number and intensity of symptoms (vomiting and nausea).
Subject is at least 18 years of age, able to understand the study procedures, and agrees to participate in the study by providing written informed consent
Subject has histologically or cytologically proven endometrial cancer
Patients were required to have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
Adequate organ function allowing the patient to receive taxane-platinum combination therapy with or without immunotherapy according to clinical practice and opinion of treating physician
They will experience emesis within the 24 hours before receipt of 1 course of chemotherapy
will be scheduled to radiation therapy to the abdomen or pelvis within 1 week before day 1 or between day 1 and 5
Will be scheduled to undergo bone marrow or stem-cell transplant
Chronic systemic corticosteroid use